AbbVie
ABBV
$137.56
Share price
-0.76%
Change (1 day)
-8.29%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
AbbVie (ABBV) - Net assets
Net assets on the balance sheet as of December 2022 : $17.28 B
According to AbbVie's latest financial reports the company has $17.28 B in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
AbbVie - Net assets on balance sheet (from 2011 to 2022)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2022-12-31 | $17.28 B | 11.99% |
| 2021-12-31 | $15.43 B | 17.86% |
| 2020-12-31 | $13.09 B | -260.27% |
| 2019-12-31 | $-8.18 B | -3.24% |
| 2018-12-31 | $-8.45 B | -265.71% |
| 2017-12-31 | $5.09 B | 9.94% |
| 2016-12-31 | $4.63 B | 17.52% |
| 2015-12-31 | $3.94 B | 126.46% |
| 2014-12-31 | $1.74 B | -61.22% |
| 2013-12-31 | $4.49 B | 33.57% |
| 2012-12-31 | $3.36 B | -72.49% |
| 2011-12-31 | $12.22 B | -22.16% |
| 2010-12-31 | $15.70 B |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $95.91 B | 454.84% | 🇺🇸 USA |
 Eli Lilly LLY | $11.29 B | -34.66% | 🇺🇸 USA |
 Amgen AMGN | $5.34 B | -69.06% | 🇺🇸 USA |
 Biogen BIIB | $13.78 B | -20.25% | 🇺🇸 USA |
 Gilead Sciences GILD | $20.93 B | 21.13% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $31.88 B | 84.45% | 🇺🇸 USA |
 AstraZeneca AZN | $35.81 B | 107.16% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $14.01 B | -18.94% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $1.68 B | -90.26% | 🇺🇸 USA |